Tandem Diabetes Care shares are trading lower after Barclays maintained an Overweight rating on the stock but lowered its price target from $71 to $62.
Portfolio Pulse from Benzinga Newsdesk
Barclays has maintained an Overweight rating on Tandem Diabetes Care but lowered its price target from $71 to $62. This has led to a decrease in Tandem's share price.
August 07, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tandem Diabetes Care's share price is expected to be negatively impacted in the short term due to Barclays lowering its price target.
Barclays, a major financial institution, has lowered its price target for Tandem Diabetes Care, indicating a less optimistic outlook for the company's stock. This news is likely to negatively impact investor sentiment and could lead to a decrease in Tandem's share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100